Patents by Inventor Karina VILLAR GOMEZ-DE LAS HERAS

Karina VILLAR GOMEZ-DE LAS HERAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treating von Hippel-Lindau disease
    Patent number: 11730707
    Abstract: The invention relates to the use of a selective ?2 adrenergic receptor antagonist for treating and preventing a tumor in a patient with von Hippel-Lindau syndrome. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating and preventing a hemangioblastoma in VHL syndrome patients.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: August 22, 2023
    Assignees: ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU-VHL, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Luisa María Botella Cubells, Virginia Albiñana Díaz, Karina Villar Gomez-De Las Heras
  • TREATMENT AND PREVENTION OF GLIOBLASTOMA
    Publication number: 20220008362
    Abstract: The invention relates to the use of a selective ?2 adrenergic receptor antagonist for treating glioma. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating a glioblastoma in a patient.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 13, 2022
    Inventors: José María SÁNCHEZ-PUELLES GONZÁLEZ-CARVAJAL, Luisa María BOTELLA CUBELLS, Tania AGUADO SANCHEZ, Ángel CUESTA MARTÍNEZ, Virginia ALBIÑANA DÍAZ, Karina VILLAR GOMEZ-DE LAS HERAS
  • COMPOUNDS FOR TREATING VON HIPPEL-LINDAU DISEASE
    Publication number: 20200323798
    Abstract: The invention relates to the use of a selective ?2 adrenergic receptor antagonist for treating and preventing a tumor in a patient with von Hippel-Lindau syndrome. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating and preventing a hemangioblastoma in VHL syndrome patients.
    Type: Application
    Filed: August 6, 2018
    Publication date: October 15, 2020
    Inventors: Luisa María BOTELLA CUBELLS, Virginia ALBIÑANA DÍAZ, Karina VILLAR GOMEZ-DE LAS HERAS